AstraZeneca and UNICEF set out youth health programme in Egypt
A new five-year partnership targets 250 schools and 500 youth centres for non-communicable disease prevention and youth-responsive services. The programme plans to train and support 5,000 young people in Egypt.
UNICEF and AstraZeneca announced on 24 September a new partnership in Egypt to support youth engagement in preventing non-communicable diseases. UNICEF’s 27 September press release said the programme phase covers 2026–2030 and focuses on young people aged 10–19.
Targets for Egypt include training and supporting 5,000 young people, equipping 250 schools and 500 youth centres with youth-responsive services, and training 1,500 teachers, 500 youth officers or coaches and 1,000 outreach stakeholders. These are plans for the new phase; the release does not report its outcomes.
MSF and Epicentre launched BRAVO on 19 September to study the use of ERVEBO among 20,000 frontline workers in Ituri and North Kivu; the study will include vaccination and follow-up.
Hamad Medical Corporation says it has performed Qatar’s first subperiosteal jaw implant and reconstruction using three-dimensional imaging and virtual surgical planning. The procedure used custom components for a patient who was not suited to conventional implants.
A new clinic at Hamad General Hospital brings pulmonary and sleep medicine together with psychiatry to assess and treat non-respiratory sleep disorders in adults. Home sleep studies and overnight polysomnography may be used when needed.
Google Analytics can measure visits and site activity using cookies if you allow it. You can change your choice later.
Measurement and privacy details
Google Analytics measurement starts only if you allow it. After consent, automatic measurement may cover scrolls, outbound link clicks, downloads, video engagement, site searches and basic form interactions; search terms may be detected from URL parameters. This site’s own code does not send form field values; email redaction in automatic measurement is best-effort, not guaranteed. Our manual page-view event uses a cleaned URL. You can change your choice later. Visits that begin with consent may also send numeric LCP, INP and CLS performance measurements after Analytics loads. A first or later grant starts this on the next page load; withdrawing consent stops these performance reports for this page. The preference cookie lasts six months; advertising measurement and personalization stay off.
Your browser is sending a Global Privacy Control signal. Analytics is off by default; you may explicitly change this choice here.
